News

Altus is developing ALTU-238 as a subcutaneously administered, long-acting formulation of rhGH that employs the company’s proprietary protein crystallization and formulation technology. Sandoz supplied rhGH for Altus’s completed

Designed for the restorative general dentist, Biolase’s Waterlase C100 is said to provide clinical procedures including cavity preparation, early stage periodontal therapy and soft tissue procedures with more

The test is based upon Zeus’s own proprietary technology utilizing the enrichment and nucleic acid amplification of a target pathogen. In addition to significantly improving assay performance over

Under this agreement, Sangamo will provide a non-exclusive, worldwide research license for the use of its proprietary zinc finger nuclease (ZFN) technology in the development of transgenic animals.

Pearl 1 is fully enrolled with over 475 non-dialysis patients from over 70 sites in the US. The Hematide Phase III program, involving a total of approximately 2,400

The new facility will be used for manufacturing, R&D and administrative functions. It is especially suited to support FDA-compliant manufacturing of the company’s human stem cell products for

According to the company, these peptides were specifically designed to elicit a T cell response targeting CD133 positive cancer stem cells that have been identified in a number

Mr Frank will remain as president and CEO of Nexcore Technology, an original equipment manufacturer (OEM) of medical devices with headquarters in Waldwick, New Jersey. Prior to founding

The clinical study is a Phase Ib placebo-controlled, single-center dose ranging study. The primary objectives are to evaluate safety and tolerability and to determine preliminary pharmacokinetics of AZX100